NLM logo
444 results
  1. ... for global state and for low dose risperidone or aripiprazole (no statistically ... weight gain, continuous measure of weight gain and increased appetite ( ...
  2. ... et al 2017 ]. With non-volitional feeding, too rapid and excessive weight gain ... this is most significant for lower extremity asymmetry because of the impact ...
  3. ... of weight gain and increased the risk of clinically significant weight gain when compared with placebo at the end of ...
  4. ... significant weight loss (or failure to achieve expected weight gain or faltering growth in children); significant nutritional deficiency; dependence on enteral feeding or oral ...
  5. ... prepubertal females (* i.e., without a history of significant gain or loss of body fat or weight) Bilateral piezogenic papules* of the heel (* i.e., ...
  6. ... with cystic fibrosis aged ≥5 years showed a clinically significant difference in weight (measured as change in kg) between the group of participants receiving an appetite stimulant (megestrol acetate or cyproheptadine hydrochloride) and the group receiving placebo at ...
  7. ... Olsen 2007 looked at the ability of seven clinically used criteria for ‘moderate’ failure to thrive to identify significant undernutrition defined as the combination of slow conditional weight gain and low BMI: body mass index < 9 th ...
  8. ... GDG recommended the use of VLCDs in patients clinically assessed by the health care professional as likely to benefit from rapid weight loss in these or analogous circumstances. The GDG noted that there is ...
  9. ... of anticonvulsants and antipsychotics reported weight gain/loss or mean weight at endpoint. Weights are in kilograms. This was not reported by trials of antidepressants. Those taking olanzapine showed a statistically significant weight gain of 2.72 kg in studies lasting between ...
  10. ... neurological signs signs and symptoms of inflammatory arthritis or connective tissue disease signs and symptoms of cardiorespiratory disease significant weight loss sleep apnoea clinically significant lymphadenopathy. [1.2.1.4] Re-assessment ...
first · previous · 1 · 2 · 3 · 4 · 5 · 6 · 7 · 8 · 9 · 10 · next · last